Gastroesophageal Reflux Disease Overview
Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus. It is one of the most commonly diagnosed digestive disorders in the US with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs and adversely affects the quality of life.
“Gastroesophageal Reflux Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastroesophageal Reflux Disease Market.
The Gastroesophageal Reflux Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Gastroesophageal Reflux Disease Pipeline Report:
Route of Administration
Gastroesophageal Reflux Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Molecule Type
Products have been categorized under various Molecule types, such as
Gastroesophageal Reflux Disease Pipeline Therapeutics Assessment
DelveInsight’s Gastroesophageal Reflux Disease Report covers around 12+ products under different phases of clinical development like-
Some of the key companies in the Gastroesophageal Reflux Disease Therapeutics Market include:
Key companies developing therapies for Gastroesophageal Reflux Disease are – AstraZeneca; Eisai Co. Ltd.; GSK plc.; Takeda Pharmaceutical Company Limited.; Ironwood Pharmaceuticals, Inc.; Johnson & Johnson Services; Inc.; SFJ Pharmaceuticals; Sebela Pharmaceuticals; Phathom Pharmaceuticals Inc.; Camber Pharmaceuticals Inc., and others.
Emerging Gastroesophageal Reflux Disease Drugs Under Different Phases of Clinical Development Include:
Get a Free Sample PDF Report to know more about Gastroesophageal Reflux Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-pipeline-insight
Gastroesophageal Reflux Disease Pipeline Analysis:
The Gastroesophageal Reflux Disease pipeline report provides insights into
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Gastroesophageal Reflux Disease product details are provided in the report. Download the Gastroesophageal Reflux Disease pipeline report to learn more about the emerging Gastroesophageal Reflux Disease therapies
Gastroesophageal Reflux Disease Pipeline Market Drivers
Gastroesophageal Reflux Disease Pipeline Market Barriers
Scope of Gastroesophageal Reflux Disease Pipeline Drug Insight
Request for Sample PDF Report for Gastroesophageal Reflux Disease Pipeline Assessment and clinical trials
Table of Contents
1
Gastroesophageal Reflux Disease Report Introduction
2
Gastroesophageal Reflux Disease Executive Summary
3
4
Gastroesophageal Reflux Disease- Analytical Perspective In-depth Commercial Assessment
5
Gastroesophageal Reflux Disease Pipeline Therapeutics
6
Gastroesophageal Reflux Disease Late Stage Products (Phase II/III)
7
Gastroesophageal Reflux Disease Mid Stage Products (Phase II)
8
Gastroesophageal Reflux Disease Early Stage Products (Phase I)
9
Gastroesophageal Reflux Disease Preclinical Stage Products
10
Gastroesophageal Reflux Disease Therapeutics Assessment
11
Gastroesophageal Reflux Disease Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Gastroesophageal Reflux Disease Key Companies
14
Gastroesophageal Reflux Disease Key Products
15
Gastroesophageal Reflux Disease Unmet Needs
16
Gastroesophageal Reflux Disease Market Drivers and Barriers
17
Gastroesophageal Reflux Disease Future Perspectives and Conclusion
18
Gastroesophageal Reflux Disease Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Gastroesophageal Reflux Disease drugs and therapies
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/r-and-d-analysis